Targeted Radiolabeled Compounds in Glioma Therapy
Malignant gliomas of World Health Organization (WHO) grades II-IV represent the largest entity within the group of intrinsic brain tumors and are graded according to their pathophysiological features with survival times between more than 10 years (WHO II) and only several months (WHO IV). Gliomas arise from astrocytic or oligodendrocytic precursor cells and exhibit an infiltrative growth pattern lacking a clearly identifiable tumor border. The development of effective treatment strategies of the invasive tumor cell front represents the main challenge in glioma therapy.
Source: Seminars in Nuclear Medicine - Category: Nuclear Medicine Authors: Dominik Cordier, Leszek Krolicki, Alfred Morgenstern, Adrian Merlo Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Glioma | Health | International Medicine & Public Health | Neurology | Nuclear Medicine | Radiology | WHO